Relative to the AD model group, DHCL selectively down-regulated p-NF-κB p65/NF-κB p65 (P < 0.001), whereas MFXD concurrently reduced p-NF-κB p65/NF-κB p65, MMP-9/β-actin, and p-Tau/Tau (P < 0.001, P < 0.05, and P < 0.001, respectively) and restored p-GSK-3β/GSK-3β (P < 0.01). Here, MAPT is linked to Alzheimer disease.